Farther Finance Advisors
PRME icon

Farther Finance Advisors’s Prime Medicine PRME Stock Holding History

Farther Finance Advisors’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-55
Closed -$203 – 6292
2026
Q2 		$203 Sell
55
-99
-64% -$329 ﹤0.01% 5716
2026
Q1 		$522 Buy
154
+83
+117% +$316 ﹤0.01% 5259
2025
Q4 		$246 Hold
71
– – ﹤0.01% 5179
2025
Q3 		$393 Buy
71
+45
+173% +$183 ﹤0.01% 4597
2025
Q2 		$64 Sell
26
-10,737
-100% -$16.6K ﹤0.01% 4356
2025
Q1 		$19.2K Buy
10,763
+10,737
+41,296% +$27.4K ﹤0.01% 2406
2024
Q4 		$76 Hold
26
– – ﹤0.01% 3829
2024
Q3 		$101 Hold
26
– – ﹤0.01% 3775
2024
Q2 		$142 Hold
26
– – ﹤0.01% 3549
2024
Q1 		$176 Buy
+26
New +$197 ﹤0.01% 3296

Other funds holding PRME

GAA
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

Farther Finance Advisors's PRME Position: Q3 2026 in Review

Farther Finance Advisors sold out of Prime Medicine (PRME) in Q3 2026, closing a stake of 55 shares — an estimated $203 sold.

Farther Finance Advisors first reported a position in PRME in Q1 2024 and held it in 10 quarters. The position peaked at $19.2K in Q1 2025. 4 funds tracked by Wall St. Rank hold PRME as of Q3 2026.

  • Farther Finance Advisors reported no remaining Prime Medicine position as of Q3 2026 after selling out during the quarter.
  • Farther Finance Advisors sold 55 Prime Medicine shares in Q3 2026, an estimated $203.
  • Farther Finance Advisors first reported a position in Prime Medicine in Q1 2024 and held it in 10 quarters.
  • Farther Finance Advisors's Prime Medicine position peaked at $19.2K in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Prime Medicine as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.